The leading studies in 2016 on acute coronary syndromes focused on strategies of acute coronary management, from the influence of revascularization timing on outcomes, to selection of second-generation antiplatelet therapy and the utility of monitoring platelet function in patients at high risk of coronary artery disease.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Wallentin, L. et al. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II investigators. Fast revascularisation during instability in coronary artery disease. Lancet 356, 9–16 (2000).
Wallentin, L. et al. Early invasive versus non-invasive treatment in patients with non-ST-elevation acute coronary syndrome (FRISC-II): 15 year follow-up of a prospective, randomised, multicentre study. Lancet 388, 1903–1911 (2016).
Kelbæk, H. et al. Deferred versus conventional stent implantation in patients with ST-segment elevation myocardial infarction (DANAMI 3-DEFER): an open-label, randomised controlled trial. Lancet 387, 2199–2206 (2016).
Roe, M. T. et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N. Engl. J. Med. 367, 1297–1309 (2012).
Wallentin, L. et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361, 1045–1057 (2009).
Motovska, Z. et al. Prasugrel versus ticagrelor in patients with acute myocardial infarction treated with primary percutaneous coronary intervention: multicenter randomized PRAGUE-18 study. Circulation 134, 1603–1612 (2016).
Price, M. J. et al. Standard- versus high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 305, 1097–1105 (2011).
Collet, J. P. et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N. Engl. J. Med. 367, 2100–2109 (2012).
Cayla, G. et al. Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial. Lancet 388, 2015–2022 (2016).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author is a consultant for Abbott Vascular, Biosensors International, Biotronik, Boston Scientific, Medtronic, and St. Jude Medical; he is in the speakers' bureau of AstraZeneca, Boston Scientific, and Merck; and has received grant support from AstraZeneca, Biosensors International, Biotronik, Boston Scientific, and Edwards Lifesciences.
Rights and permissions
About this article
Cite this article
Waksman, R. Assessing strategies to improve patient management. Nat Rev Cardiol 14, 77–78 (2017). https://doi.org/10.1038/nrcardio.2016.210
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2016.210
